Mylan (MYL) Suit Against FDA Over Hear Drug Dismissed - Bloomberg

December 27, 2012 1:56 PM EST
Mylan, Inc. (NASDAQ: MYL) saw a little volume move higher following headlines that its suit against the FDA over a generic heart drug was dismissed, according to Bloomberg headlines.

Shares are down 1.4 percent on the session, but off of lows.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Litigation

Add Your Comment